Indication
Anxiety associated with menopause
Anxiety associated with menopause refers to the onset or exacerbation of affective and somatic anxiety symptoms occurring during the climacteric transition, predominantly affecting perimenopausal and postmenopausal women. Read more about Anxiety associated with menopause
0 drugs 0 manufacturers
Drugs that treat it
Common Anxiety associated with menopause therapies.
No drugs are available
This indication does not currently contain public drugs.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAnxiety associated with menopause refers to the onset or exacerbation of affective and somatic anxiety symptoms occurring during the climacteric transition, predominantly affecting perimenopausal and postmenopausal women.
This condition involves both the central nervous and endocrine systems, driven by neuroendocrine dysregulation linked to fluctuating and declining ovarian steroid hormones, particularly estradiol and progesterone.
These hormonal shifts alter hypothalamic-pituitary-adrenal axis reactivity and disrupt key neurotransmitter networks, including gamma-aminobutyric acid and serotonergic pathways.
Clinically, it presents as persistent nervousness, excessive worry, cognitive disturbances, and episodic panic, frequently compounded by somatic manifestations such as sleep fragmentation, palpitations, and concurrent vasomotor symptoms.
- hopkinsmedicine.org
Anxiety associated with menopause refers to the onset or exacerbation of affective and somatic anxiety symptoms occurring during the climacteric transition, predominantly affecting perimenopausal and postmenopausal women This condition involves both the central nervous and endocrine systems, driven by neuroendocrine dysregulation linked to fluctuating and declining ovarian steroid hormones, particularly estradiol and progesterone These hormonal shifts alter hypothalamic-pituitary-adrenal axis re...
- reachmd.com
Anxiety associated with menopause refers to the onset or exacerbation of affective and somatic anxiety symptoms occurring during the climacteric transition, predominantly affecting perimenopausal and postmenopausal women
- therapygroupdc.com
This condition involves both the central nervous and endocrine systems, driven by neuroendocrine dysregulation linked to fluctuating and declining ovarian steroid hormones, particularly estradiol and progesterone These hormonal shifts alter hypothalamic-pituitary-adrenal axis reactivity and disrupt key neurotransmitter networks, including gamma-aminobutyric acid and serotonergic pathways
- clevelandclinic.org
Clinically, it presents as persistent nervousness, excessive worry, cognitive disturbances, and episodic panic, frequently compounded by somatic manifestations such as sleep fragmentation, palpitations, and concurrent vasomotor symptoms
- menopause.org
Clinically, it presents as persistent nervousness, excessive worry, cognitive disturbances, and episodic panic, frequently compounded by somatic manifestations such as sleep fragmentation, palpitations, and concurrent vasomotor symptoms
Personalize your experience
Follow Anxiety associated with menopause and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.